Disclosed herein are fluorinated arylalkylaminocarboxamide derivatives of formula (I) wherein the substituents are as defined in the specification and pharmaceutically salts thereof. Also disclosed are pharmaceutical compositions containing the compounds as active ingredients and their use as sodium and/or calcium channel modulators intended for preventing, alleviating and curing a wide range of pathologies, including neurological, psychiatric, cardiovascular, inflammatory, ophtalmic, urolological, and gastrointestinal diseases, where the sodium and/or calcium channel have a pathological role. Examples of the compounds include 2-[2,2-difluoro-2-(3-butoxyphenyl)-ethylamino]-N,N-dimethyl-acetamide, hydrochloride and 2-[2-fluoro-2-(3-butoxyphenyl)-ethylamino]-N,N-dimethyl-acetamide, hydrochloride.
